- Home
- BGI vs IBIO Comparison
BGI vs IBIO Comparison
Compare BGI & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- IBIO
- Stock Information
- Founded
- BGI 1879
- IBIO 2008
- Country
- BGI Canada
- IBIO United States
- Employees
- BGI N/A
- IBIO N/A
- Industry
- BGI
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- IBIO Health Care
- Exchange
- BGI Nasdaq
- IBIO Nasdaq
- Market Cap
- BGI 18.0M
- IBIO 15.9M
- IPO Year
- BGI 2005
- IBIO N/A
- Fundamental
- Price
- BGI $0.91
- IBIO $0.77
- Analyst Decision
- BGI
- IBIO Strong Buy
- Analyst Count
- BGI 0
- IBIO 3
- Target Price
- BGI N/A
- IBIO $4.87
- AVG Volume (30 Days)
- BGI 57.4K
- IBIO 481.5K
- Earning Date
- BGI 07-15-2025
- IBIO 05-02-2025
- Dividend Yield
- BGI N/A
- IBIO N/A
- EPS Growth
- BGI N/A
- IBIO N/A
- EPS
- BGI N/A
- IBIO N/A
- Revenue
- BGI $131,596,265.00
- IBIO $375,000.00
- Revenue This Year
- BGI N/A
- IBIO $36.00
- Revenue Next Year
- BGI N/A
- IBIO N/A
- P/E Ratio
- BGI N/A
- IBIO N/A
- Revenue Growth
- BGI 4.01
- IBIO 650.00
- 52 Week Low
- BGI $0.76
- IBIO $0.64
- 52 Week High
- BGI $2.99
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- BGI 51.08
- IBIO 39.38
- Support Level
- BGI $0.86
- IBIO $0.81
- Resistance Level
- BGI $0.93
- IBIO $0.99
- Average True Range (ATR)
- BGI 0.07
- IBIO 0.11
- MACD
- BGI 0.01
- IBIO 0.02
- Stochastic Oscillator
- BGI 72.29
- IBIO 3.67
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.